Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Pharmacology of Anti-Cancer Drugs

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1635953

SIK2 activates the autophagy‒apoptosis pathway through SP1 regulation to inhibit the progression of hepatocellular carcinoma

Provisionally accepted
  • 1First Affiliated Hospital of Anhui Medical University, Hefei, China
  • 2Anhui Public Health Clinical Center, Hefei, China
  • 3The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

The final, formatted version of the article will be published soon.

Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer globally and is the fourth leading cause of cancer-related mortality, characterized by limited treatment options and an unfavorable prognosis. Salt-inducible kinase 2 (SIK2), a member of the AMP-activated protein kinase (AMPK) family, regulates cellular processes, including metabolism, autophagy, and apoptosis. However, its specific role in HCC remains unclear. This study assessed the clinical relevance and biological function of SIK2 in HCC via bioinformatics, immunohistochemistry (IHC), cell assays, signaling pathway analyses, and animal models. The results demonstrated that high SIK2 expression was associated with improved patient survival, modulation of the immune microenvironment, an enhanced response to immunotherapy, and suppression of tumor progression. Mechanistically, SIK2 inhibited HCC cell proliferation, migration, and invasion and promoted autophagy through increased autophagic flux. However, due to impaired autophagic flux, apoptosis is induced. This study highlights the significant clinical relevance of SIK2 in primary liver cancer and its multifaceted roles in tumor biology. SIK2 serves as an independent protective prognostic factor and may exert a tumor-suppressive effect by modulating the tumor microenvironment, autophagy, and apoptosis. Elevated SIK2 expression was strongly linked to better prognosis and enhanced immunotherapy responsiveness in HCC patients, highlighting its promise as both a prognostic indicator and a potential therapeutic target. Future research should focus on clarifying the precise molecular mechanisms involving SIK2 and investigating its potential for clinical therapeutic applications.

Keywords: Hepatocellular Carcinoma, SIK2, Autophagy, Apoptosis, signaling pathway, tumor suppression

Received: 27 May 2025; Accepted: 22 Sep 2025.

Copyright: © 2025 Fan, Ma, Zhang, Hou, 牛, Wang, Zhang, Xia and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Jinguo Zhang, zhangjg2022@ustc.edu.cn
Yunhong Xia, yhxia12@sina.com
Yueyin Pan, panyueyin@ustc.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.